HomeAI · summaries
Storia in 3 fonti
Top FDA gene and cell therapy regulator to step down
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
FDA’s top gene therapy regulator is leaving his role
The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
- ·
biopharmadive.com
Top FDA gene and cell therapy regulator to step down
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
